502 related articles for article (PubMed ID: 17534875)
1. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
[TBL] [Abstract][Full Text] [Related]
2. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Park YH; Lee SY; Lee JS
Lung Cancer; 2009 Jan; 63(1):115-20. PubMed ID: 18221820
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis.
Campa D; Müller P; Edler L; Knoefel L; Barale R; Heussel CP; Thomas M; Canzian F; Risch A
Int J Cancer; 2012 Dec; 131(12):2920-8. PubMed ID: 22473764
[TBL] [Abstract][Full Text] [Related]
4. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Kim HT; Lee JS
Lung Cancer; 2008 Jan; 59(1):69-75. PubMed ID: 17766002
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan pathway genotype analysis to predict pharmacokinetics.
Mathijssen RH; Marsh S; Karlsson MO; Xie R; Baker SD; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2003 Aug; 9(9):3246-53. PubMed ID: 12960109
[TBL] [Abstract][Full Text] [Related]
6. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.
Jada SR; Lim R; Wong CI; Shu X; Lee SC; Zhou Q; Goh BC; Chowbay B
Cancer Sci; 2007 Sep; 98(9):1461-7. PubMed ID: 17627617
[TBL] [Abstract][Full Text] [Related]
7. Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).
Fujita K; Nagashima F; Yamamoto W; Endo H; Sunakawa Y; Yamashita K; Ishida H; Mizuno K; Matsunaga M; Araki K; Tanaka R; Ichikawa W; Miya T; Narabayashi M; Akiyama Y; Kawara K; Ando Y; Sasaki Y
Biol Pharm Bull; 2008 Nov; 31(11):2137-42. PubMed ID: 18981587
[TBL] [Abstract][Full Text] [Related]
8. Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy.
Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Sirilerttrakul S; Chamnanphon M; Puangpetch A; Sukasem C
Sci Rep; 2020 Aug; 10(1):13486. PubMed ID: 32778670
[TBL] [Abstract][Full Text] [Related]
9. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
Chen S; Villeneuve L; Jonker D; Couture F; Laverdière I; Cecchin E; Innocenti F; Toffoli G; Lévesque E; Guillemette C
Pharmacogenet Genomics; 2015 Dec; 25(12):573-83. PubMed ID: 26352872
[TBL] [Abstract][Full Text] [Related]
10. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
[TBL] [Abstract][Full Text] [Related]
11. [Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
Sun ZW; Wang XC; Gao J; Li J; Li YY; Dang YZ; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):524-8. PubMed ID: 23801203
[TBL] [Abstract][Full Text] [Related]
12. Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.
Akamine Y; Miura M; Sunagawa S; Kagaya H; Yasui-Furukori N; Uno T
Xenobiotica; 2010 Nov; 40(11):782-9. PubMed ID: 20839930
[TBL] [Abstract][Full Text] [Related]
13. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
Zamboni WC; Ramanathan RK; McLeod HL; Mani S; Potter DM; Strychor S; Maruca LJ; King CR; Jung LL; Parise RA; Egorin MJ; Davis TA; Marsh S
Invest New Drugs; 2006 Sep; 24(5):393-401. PubMed ID: 16505951
[TBL] [Abstract][Full Text] [Related]
14. Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy.
Erdilyi DJ; Kámory E; Csókay B; Andrikovics H; Tordai A; Kiss C; Filni-Semsei A; Janszky I; Zalka A; Fekete G; Falus A; Kovács GT; Szalai C
Pharmacogenomics J; 2008 Oct; 8(5):321-7. PubMed ID: 17938643
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.
Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Jang IJ; Lee DH; Lee JS
J Clin Oncol; 2006 May; 24(15):2237-44. PubMed ID: 16636344
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ
J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
de Jong FA; Scott-Horton TJ; Kroetz DL; McLeod HL; Friberg LE; Mathijssen RH; Verweij J; Marsh S; Sparreboom A
Clin Pharmacol Ther; 2007 Jan; 81(1):42-9. PubMed ID: 17185998
[TBL] [Abstract][Full Text] [Related]
19. ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients.
Qu J; Zhou BT; Yin JY; Xu XJ; Zhao YC; Lei GH; Tang Q; Zhou HH; Liu ZQ
CNS Neurosci Ther; 2012 Aug; 18(8):647-51. PubMed ID: 22630058
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.
Zhou Q; Sparreboom A; Tan EH; Cheung YB; Lee A; Poon D; Lee EJ; Chowbay B
Br J Clin Pharmacol; 2005 Apr; 59(4):415-24. PubMed ID: 15801936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
